| Title |
Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding
|
|---|---|
| Published in |
PLOS ONE, June 2012
|
| DOI | 10.1371/journal.pone.0039045 |
| Pubmed ID | |
| Authors |
Gerald R. Nakamura, Dora P. A. J. Fonseca, Sara M. O'Rourke, Aaron L. Vollrath, Phillip W. Berman |
| Abstract |
Recombinant gp120 (MN-rgp120) was a major component of the AIDSVAX B/E vaccine used in the RV144 trial. This was the first clinical trial to show that vaccination could prevent HIV infection in humans. A recent RV144 correlates of protection study found that protection correlated with the presence of antibodies to the V2 domain. It has been proposed that antibodies to the α4β7 binding site in the V2 domain might prevent HIV-1 infection by blocking the ability of virions to recognize α4β7 on activated T-cells. In this study we investigated the specificity of monoclonal antibodies (MAbs) to the V2 domain of MN-rgp120 and examined the possibility that these antibodies could inhibit the binding of MN-rgp120 to the α4β7 integrin. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Portugal | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 28 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 32% |
| Student > Ph. D. Student | 9 | 29% |
| Student > Postgraduate | 3 | 10% |
| Student > Master | 3 | 10% |
| Student > Bachelor | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 2 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 14 | 45% |
| Immunology and Microbiology | 5 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Medicine and Dentistry | 3 | 10% |
| Veterinary Science and Veterinary Medicine | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 3 | 10% |